Study authors used machine learning approaches to identify unique clusters of children and youth with juvenile idiopathic arthritis, both at first presentation and during follow-up.
Researchers assessed the clinical significance of serum IL-18 levels for the diagnosis of and prediction of disease course in systemic juvenile idiopathic arthritis.
Researchers assessed pain perception and sensitivity, and self-reported pain in young adults with long-standing juvenile idiopathic arthritis.
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
Researchers analyzed the response to biologic treatment in juvenile idiopathic arthritis based on the timing of initiation of the treatment.
Researchers investigated the feasibility, acceptability, and diagnostic performance of imaging-based surveillance for uveitis.
Researchers determined the temporal association between arthritis and uveitis activity in children with juvenile idiopathic arthritis associated with uveitis.
The FDA has approved Simponi Aria for the treatment of patients aged 2 years and older with active polyarticular juvenile idiopathic arthritis.
Patients treated with tofacitinib experienced significantly fewer disease flares compared with placebo.
An international panel of pediatric rheumatologists created a new score to address a lack in the 4-item JADAS in quantifying the burden of extra-articular manifestations of juvenile idiopathic arthritis.
